The two federal offices that decide which medicines reach American pharmacies and which vaccines reach American clinics now have permanent leaders. The Department of Health and Human Services announced four senior selections at the Food and Drug Administration, filling the top jobs at the drug, biologics, and tobacco centers and creating a new deputy commissioner post for technology and artificial intelligence.
For patients, the practical stakes sit in the pipeline. The Center for Drug Evaluation and Research reviews prescription and over-the-counter medicines and monitors them after approval. The Center for Biologics Evaluation and Research handles vaccines, blood products, and cell and gene therapies. All three centers had been running under acting directors, a status that tends to slow contested decisions and leave policy direction ambiguous.
